Experimental cell therapy takes on Hard-to-Treat blood cancers

NCT ID NCT04155710

Completed Disease control Sponsor: Iovance Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new cell therapy called IOV-2001 in 7 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that had stopped responding to standard drugs. The therapy uses a patient's own immune cells, which are collected, processed, and then infused back along with interleukin-2 to boost their activity. The main goals were to find the right dose and check for safety and any signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IOV-2001 (a cell therapy made from the patient's own immune cells) followed by interleukin-2 (IL-2)
What this could lead to: If successful, this could offer a new treatment option for patients with CLL or SLL that has stopped responding to standard drugs like ibrutinib.
What could go wrong: This was a very early, small trial (only 7 people) with no published results yet. Cell therapies can cause serious side effects, and it is unclear if this approach will work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA SMALL LYMPHOCYTIC LYMPHOMA

Contacts and locations

Locations

Allegheny Health

Pittsburgh, Pennsylvania, 15224, United States
Baptist Cancer Center

Memphis, Tennessee, 38120, United States
Duke University

Durham, North Carolina, 27710, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Ohio State University

Columbus, Ohio, 43210, United States
University of Cincinnati Medical Center

Cincinnati, Ohio, 45219, United States
University of Utah, Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.